Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.

BACKGROUND The objective was to evaluate the value of DNA ploidy using high-resolution image cytometry in predicting long-term survival of patients with early ovarian cancer. PATIENTS AND METHODS A retrospective analysis of 284 cases with FIGO stage I ovarian carcinoma treated during the period 1982-1989 was performed. Clinical follow-up information was available for all patients. RESULTS Patients with diploid and tetraploid tumors had a 10-year relapse-free survival of 95% and 89%, respectively, compared with 70% and 29% for polyploid and aneuploid tumors, respectively. DNA ploidy analysis was the strongest predictor of survival in multivariate analysis (diploid/tetraploid versus polyploid/aneuploid; relative hazard 9.0) followed by histological grade, including clear cell tumors in the group of poorly differentiated tumors (grade 1-2 versus grade 3 or clear cell; relative hazard 2.7), and FIGO stage (Ib/Ic versus Ia; relative hazard 2.0). In a stratified Kaplan-Meier analysis, patients with grade 1-2, diploid or tetraploid tumors had a 10-year relapse-free survival of 95%, forming a low-risk group. Patients with grade 3 or clear cell, diploid or tetraploid tumors had 10-year relapse-free survival of 86%, forming an intermediate-risk group, while all patients with aneuploid/polyploid tumors formed a high-risk group, with 10-year relapse-free survival of 34%. CONCLUSIONS This study points to the importance of including DNA ploidy analysis by image cytometry when selecting patients with early ovarian cancer for adjuvant treatment after surgery.

[1]  V. Abeler,et al.  Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer , 1992, Cancer.

[2]  I W Taylor,et al.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[3]  A. Reith,et al.  Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer. , 1992, Cytometry.

[4]  K. Nielsen,et al.  Prognostic factors and adjuvant treatment in early epithelial ovarian cancer , 1992, International Journal of Gynecologic Cancer.

[5]  K. Kinzler,et al.  Cancer-susceptibility genes. Gatekeepers and caretakers. , 1997, Nature.

[6]  G. Fleuren,et al.  Watch and wait after careful surgical treatment and staging in well‐differentiated early ovarian cancer , 1991, Cancer.

[7]  Robert A. Weinberg,et al.  A checkpoint on the road to cancer , 1998, Nature.

[8]  G. Fleuren,et al.  DNA index reflects the biological behavior of ovarian carcinoma stage I-IIa. , 1996, Gynecologic Oncology.

[9]  M. Parmar,et al.  International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. , 2003, Journal of the National Cancer Institute.

[10]  A. Stenwig,et al.  Prognostic Factors in Patients With Stage I Epithelial Ovarian Cancer , 1990, Obstetrics and gynecology.

[11]  P. Philips,et al.  A study of 656 patients with "early" ovarian cancer. , 1984, Gynecologic oncology.

[12]  P. Wingo,et al.  The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? , 1991, American journal of obstetrics and gynecology.

[13]  G. Baiocchi,et al.  Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[14]  Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. , 1999 .

[15]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[16]  V. Torri,et al.  The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Joos Vandewalle,et al.  Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma , 2001, The Lancet.

[18]  M. Gore,et al.  Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. Torri,et al.  Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P) , 1995 .

[20]  T. Kunkel,et al.  Mutator Specificity and Disease: Looking over the FENce , 1997, Cell.

[21]  V. Abeler,et al.  Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. , 1993, American journal of obstetrics and gynecology.

[22]  Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument , 2000 .

[23]  M. Schemper,et al.  Prognostic factors for survival in Stage I epithelial ovarian carcinoma , 1990 .

[24]  H. Levin,et al.  A prospective comparison of DNA quantitation by image and flow cytometry. , 1990, American journal of clinical pathology.